|
|
| Products Name£º | dabigatran etexilate |
| Synonyms£º | N-[2-[4-[N-(Hexyloxycarbonyl)amidino]phenylaminomethyl]-1-methyl-1H-benzimidazol-5-ylcarbonyl]-N-(2-pyridyl)-beta-alanine ethyl ester |
| Cas No.£º | 211915-06-9 |
| Molecular Formula£º | C34H41N7O5 |
| Molecular Weight£º | 627.74 |
| Assay | 99.9% |
| Darby added group of ester is a new kind of synthesis of direct thrombin inhibitor, is the precursor of dabigatran, of non peptide thrombin inhibitors. Oral after gastrointestinal absorption in the body into dabigatran with anticoagulant activity directly. Dabigatran combination in fibrin clotting enzyme specific binding site, prevent fibrinogen cracking for fibrous protein, thereby blocking the blood coagulation cascade network last step and thrombosis. Dabigatran can from fibrin clotting enzyme mixture over from, the reversible anticoagulant effect into full play. Pharmacological effects: this product is a direct thrombin inhibitor, for pekah group of former medicine, belongs to the non peptide thrombin inhibitors. Release the latter, in the body after oral thrombin and fibrin specific loci, prevent fibrinogen cracking for fibrous protein, thereby blocking the blood coagulation cascade network last step and thrombosis |
|
|
